search
Back to results

Therapeutic Orientation Test in Thrombotic Microangiopathy (TOTEM)

Primary Purpose

Thrombotic Micro-angiopathy

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Therapeutic orientation test for TMA
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Thrombotic Micro-angiopathy focused on measuring Nephrology, Complement, Thrombotic micro-angiopathy, Diagnostic, Haemolytic and Uraemic Syndrome

Eligibility Criteria

undefined - 90 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

TMA with:

  • mechanic haemolytic anemia, undetectable haptoglobin, LDH>1.5*LNS
  • thrombopenia
  • acute kidney injury TMA on native kidney or in post-transplantation.

Exclusion Criteria:

  • DIVC patients
  • plasma exchange during 1 month before sample collection
  • treatment by Eculizumab before sample collection
  • no consent
  • not beneficiary of a social security
  • pregnancy or breastfeeding
  • patient Under guardianship

Sites / Locations

  • Montpellier University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients with Thrombotic micro-angiopathy

Arm Description

Outcomes

Primary Outcome Measures

Therapeutic orientation test sensitivity
The proportion of patients testing positive among those receiving a relevant Eculizumab treatment ( TMA resolution with treatment or presence of abnormalities in alternative complement pathway.
Therapeutic orientation test specificity
The proportion of patients testing negative among patients who did not receive Eculizumab treatment.(TMA resolution without treatment or therapeutic failure with Eculizumab).

Secondary Outcome Measures

Untreated test positive patients
The proportion of patients with positive test but untreated by Eculizumab, and who therefore could have benefited from treatment.

Full Information

First Posted
February 19, 2021
Last Updated
February 2, 2023
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT04777435
Brief Title
Therapeutic Orientation Test in Thrombotic Microangiopathy
Acronym
TOTEM
Official Title
Therapeutic Orientation Test in Thrombotic Microangiopathy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 3, 2021 (Actual)
Primary Completion Date
October 3, 2023 (Anticipated)
Study Completion Date
April 3, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block alternative complement pathway activation. To rise treatment success, Eculizumab introduction should be as early as possible. In some secondary HUS (infection, drugs…) complement is also involved as "second-hit". To date, there is no tool to confirm complement involvement in a HUS at diagnosis stage. This study suggest to evaluate a therapeutic orientation test, in order to determine the complement implication in HUS diagnosis. The test evaluates the complement deposits on endothelial cell surface in vitro, compared to a normal human serum. In order to determine the test performance, first the positive or negative results will be compared to the HUS clinical evolution, treated or not by the clinician with Eculizumab. Second, the test results will be compared to the presence of alternative complement pathway regulation abnormalities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thrombotic Micro-angiopathy
Keywords
Nephrology, Complement, Thrombotic micro-angiopathy, Diagnostic, Haemolytic and Uraemic Syndrome

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients with Thrombotic micro-angiopathy
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
Therapeutic orientation test for TMA
Intervention Description
Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
Primary Outcome Measure Information:
Title
Therapeutic orientation test sensitivity
Description
The proportion of patients testing positive among those receiving a relevant Eculizumab treatment ( TMA resolution with treatment or presence of abnormalities in alternative complement pathway.
Time Frame
Through study completion, an average of 3 years.
Title
Therapeutic orientation test specificity
Description
The proportion of patients testing negative among patients who did not receive Eculizumab treatment.(TMA resolution without treatment or therapeutic failure with Eculizumab).
Time Frame
Through study completion, an average of 3 years.
Secondary Outcome Measure Information:
Title
Untreated test positive patients
Description
The proportion of patients with positive test but untreated by Eculizumab, and who therefore could have benefited from treatment.
Time Frame
Through study completion, an average of 3 years.

10. Eligibility

Sex
All
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: TMA with: mechanic haemolytic anemia, undetectable haptoglobin, LDH>1.5*LNS thrombopenia acute kidney injury TMA on native kidney or in post-transplantation. Exclusion Criteria: DIVC patients plasma exchange during 1 month before sample collection treatment by Eculizumab before sample collection no consent not beneficiary of a social security pregnancy or breastfeeding patient Under guardianship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Moglie LE QUNITREC-DONNETTE, Professor
Phone
467330996
Ext
+33
Email
m-lequintrec-donnette@chu-montpellier.fr
Facility Information:
Facility Name
Montpellier University Hospital
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Moglie LE QUINTREC-DONNETTE, Pr

12. IPD Sharing Statement

Learn more about this trial

Therapeutic Orientation Test in Thrombotic Microangiopathy

We'll reach out to this number within 24 hrs